Freeze-dried azacitidine preparation for injection

A technology for azacitidine and freeze-dried preparations, which is applied in the field of pharmaceutical preparations, can solve the problems of reducing the stability of this product, increasing production costs, and being unable to inhibit decomposition, etc., to shorten the preparation time, shorten the freeze-drying cycle, and shorten the freeze-drying time. cycle effect

Inactive Publication Date: 2017-09-08
LUNAN PHARMA GROUP CORPORATION
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The main related substances of azacitidine for injection come from the hydrolyzate, and vitamin C, as a reduction protective agent, cannot inhibit the decomposition of this product in water, and the introduction of new components may bring unnecessary safety problems
[0008] The above-mentioned

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Freeze-dried azacitidine preparation for injection
  • Freeze-dried azacitidine preparation for injection

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0027] Example 1

[0028] 1) Prescription

[0029] Azacitidine 50g

[0030] Mannitol 50g

[0031] Water for injection to 3L

[0032] 2) Preparation of azacitidine freeze-dried powder for injection:

[0033] Accurately weigh 90% of the prescription amount of water for injection; weigh the prescription amount of azacitidine (100μm in diameter) and mannitol, mix them in a sterile bag for 10 minutes, slowly add to the water for injection, stir to dissolve. Sampling to detect the content of intermediate products; according to the intermediate test results, fill the liquid medicine in a vial with a half stopper; cool the freeze dryer to -40°C in advance, and send the filled sample into the freeze dryer for 2.5 hours; The shelf temperature is raised to -10°C at 10°C / h and kept for 8 hours; the temperature is raised to 40°C at 10°C / h and kept for 14 hours; the ultimate vacuum is then carried out for 2 hours, and the pressure rise experiment should be carried out. The experiment should satisfy ...

Example Embodiment

[0034] Example 2

[0035] 1) Prescription

[0036] Azacitidine 50g

[0037] Mannitol 50g

[0038] Water for injection to 3L

[0039] 2) Preparation of azacitidine freeze-dried powder for injection:

[0040] Accurately weigh 90% of the prescription amount of water for injection; weigh the prescription amount of azacitidine (150 μm in particle size) and mannitol, mix for 10 min in a sterile bag, slowly add to the water for injection, stir to dissolve. Sampling to detect the content of intermediate products; according to the intermediate test results, fill the liquid medicine in a vial with a half stopper; cool the freeze dryer to -40°C in advance, and send the filled sample into the freeze dryer for 2.5 hours; The shelf temperature is raised to -10°C at 10°C / h and kept for 8 hours; the temperature is raised to 40°C at 10°C / h and kept for 14 hours; the ultimate vacuum is then carried out for 2 hours, and the pressure rise experiment should be carried out. The experiment should satisfy <0....

Example Embodiment

[0041] Example 3

[0042] 1) Prescription

[0043] Azacitidine 50g

[0044] Mannitol 50g

[0045] Water for injection to 3L

[0046] 2) Preparation of azacitidine freeze-dried powder for injection:

[0047] Accurately weigh 90% of the prescription amount of water for injection; weigh the prescription amount of azacitidine (particle size of 200μm) and mannitol, mix them in a sterile bag for 10 minutes, slowly add to the water for injection, stir to dissolve. Sampling to detect the content of intermediate products; according to the intermediate test results, fill the liquid medicine in a vial with a half stopper; cool the freeze dryer to -40°C in advance, and send the filled sample into the freeze dryer for 2.5 hours; The shelf temperature is raised to -10°C at 10°C / h and kept for 8h; the temperature is raised to 40°C at 10°C / h and kept for 14h; the ultimate vacuum is then carried out for 2 hours, and the pressure rise experiment should be carried out. The experiment should satisfy <0.1p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of medicinal preparations, and particularly provides a freeze-dried azacitidine preparation for injection and a preparation method thereof. The freeze-dried azacitidine preparation for injection comprises azacitidine and a proper amount of filler, wherein the filler is preferably mannitol. The preparation method comprises the following steps: weighing the azacitidine (the particle size is controlled to be 100-200 microns) according to a prescription dosage, mixing the azacitidine with the mannitol, adding a mixture into water for injection, stirring till the mixture is completely dissolved, filtering, subpackaging, performing freeze drying, pressing a cork, rolling a cover, and packaging. The preparation method is simple in process, low in production cost and high in efficiency; visible foreign matters and related substances are qualified; the freeze-dried azacitidine preparation for injection is good in redissolution and stable in product quality.

Description

technical field [0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a freeze-dried preparation of azacitidine for injection. Background technique [0002] Myelodysplastic syndrome (MDS) is a group of diseases characterized by clonal abnormalities of hematopoietic stem cells, which can lead to hematopoietic failure and a high risk of progression to acute myeloid leukemia (AML). The disease is divided into 5 types, namely refractory anemia (RA), ring sideroblastic anemia, refractory anemia with increased blasts (REAB), refractory anemia with increased blasts-transition (RAEB) -T) and chronic myelomonocytic leukemia (CMML). [0003] Azacitidine (Azacitidine) is a DNA methyltransferase inhibitor, which can cause DNA hypomethylation and has direct cytotoxicity. It was developed by Pharmion Pharmaceutical Company of the United States. In May 2004, the FDA approved the drug Vidaza for the treatment of all subtypes of my...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/19A61K47/26A61K31/706A61P7/00A61P7/06A61P35/02
CPCA61K9/0019A61K9/19A61K31/706A61P35/02A61K47/10A61P7/06
Inventor 张贵民贾俊伟冯中
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap